首页 > 最新文献

Indian Journal of Medical Research最新文献

英文 中文
Emerging role of exosomes as a liquid biopsy tool for diagnosis, prognosis & monitoring treatment response of communicable & non-communicable diseases. 外泌体作为液体活检工具在诊断、预后和监测传染性和非传染性疾病的治疗反应方面的新作用。
IF 4.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2024-02-01 Epub Date: 2024-04-04 DOI: 10.4103/ijmr.ijmr_2344_22
Rajbala Yadav, Ajay Vir Singh, Shweta Kushwaha, Devendra Singh Chauhan

Abstract: From an initial thought of being used as a cellular garbage bin to a promising target for liquid biopsies, the role of exosomes has drastically evolved in just a few years of their discovery in 1983. Exosomes are naturally secreted nano-sized vesicles, abundant in all types of body fluids and can be isolated intact even from the stored biological samples. Being stable carriers of genetic material (cellular DNA, mRNA and miRNA) and having specific cargo (signature content of originating cells), exosomes play a crucial role in pathogenesis and have been identified as a novel source of biomarkers in a variety of disease conditions. Recently exosomes have emerged as a promising 'liquid biopsy tool'and have shown great potential in the field of non-invasive disease diagnostics, prognostics and treatment response monitoring in both communicable as well as non-communicable diseases. However, there are certain limitations to overcome which restrict the use of exosome-based liquid biopsy as a gold standard testing procedure in routine clinical practices. The present review summarizes the current knowledge on the role of exosomes as the liquid biopsy tool in diagnosis, prognosis and treatment response monitoring in communicable and non-communicable diseases and highlights the major limitations, technical advancements and future prospects of the utilization of exosome-based liquid biopsy in clinical interventions.

摘要:自1983年发现外泌体以来,外泌体的作用在短短几年内发生了翻天覆地的变化。外泌体是一种天然分泌的纳米级囊泡,在各种体液中含量丰富,即使从储存的生物样本中也能完整地分离出来。外泌体是遗传物质(细胞 DNA、mRNA 和 miRNA)的稳定载体,具有特异性货物(起源细胞的特征内容),在外泌体的发病机制中起着至关重要的作用,并已被确定为多种疾病的新型生物标志物来源。最近,外泌体已成为一种前景广阔的 "液体活检工具",在传染性和非传染性疾病的无创疾病诊断、预后和治疗反应监测领域显示出巨大的潜力。然而,基于外泌体的液体活检还存在一些需要克服的局限性,这些局限性限制了其作为金标准检测程序在常规临床实践中的应用。本综述总结了目前关于外泌体作为液体活检工具在传染性和非传染性疾病的诊断、预后和治疗反应监测中的作用的知识,并强调了在临床干预中使用基于外泌体的液体活检的主要局限性、技术进步和未来前景。
{"title":"Emerging role of exosomes as a liquid biopsy tool for diagnosis, prognosis & monitoring treatment response of communicable & non-communicable diseases.","authors":"Rajbala Yadav, Ajay Vir Singh, Shweta Kushwaha, Devendra Singh Chauhan","doi":"10.4103/ijmr.ijmr_2344_22","DOIUrl":"https://doi.org/10.4103/ijmr.ijmr_2344_22","url":null,"abstract":"<p><strong>Abstract: </strong>From an initial thought of being used as a cellular garbage bin to a promising target for liquid biopsies, the role of exosomes has drastically evolved in just a few years of their discovery in 1983. Exosomes are naturally secreted nano-sized vesicles, abundant in all types of body fluids and can be isolated intact even from the stored biological samples. Being stable carriers of genetic material (cellular DNA, mRNA and miRNA) and having specific cargo (signature content of originating cells), exosomes play a crucial role in pathogenesis and have been identified as a novel source of biomarkers in a variety of disease conditions. Recently exosomes have emerged as a promising 'liquid biopsy tool'and have shown great potential in the field of non-invasive disease diagnostics, prognostics and treatment response monitoring in both communicable as well as non-communicable diseases. However, there are certain limitations to overcome which restrict the use of exosome-based liquid biopsy as a gold standard testing procedure in routine clinical practices. The present review summarizes the current knowledge on the role of exosomes as the liquid biopsy tool in diagnosis, prognosis and treatment response monitoring in communicable and non-communicable diseases and highlights the major limitations, technical advancements and future prospects of the utilization of exosome-based liquid biopsy in clinical interventions.</p>","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":"159 2","pages":"163-180"},"PeriodicalIF":4.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11050750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140854998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacoeconomics of medicines used for geriatric individuals in a tertiary care hospital in Delhi. 德里一家三级医院老年病用药的药物经济学。
IF 4.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2024-02-01 Epub Date: 2024-04-04 DOI: 10.4103/ijmr.ijmr_2507_21
Vikram Jit Singh, Vandana Roy, Shubha Singhal, M K Daga

Background objectives: Expenditure on healthcare is a major concern in the geriatric age group. The current study was carried out to assess the expenditure patterns on medicines utilized in geriatric inpatients.

Methods: An observational study was conducted on 1000 geriatric inpatients, aged ≥60 yr, admitted to the medicine unit. Data were collected regarding demographic characteristics, prescribed medicines, expenditure incurred on medicines, appropriateness of medicines prescribed and adverse drug reactions (ADRs). Appropriateness of the prescribed medicines was determined using the American Geriatrics Society 2015 Updated Beers Criteria.

Results: Geriatric inpatients comprised 41.3 per cent of the total individuals admitted in the ward during the study period. A total of 8366 medicines were prescribed in 127 formulations. The total expenditure on prescribed medicines was INR 1,087,175 with a per capita expenditure of INR 1087.17. Parenteral medicines accounted for 91 per cent of the expenditure on medicines. Maximum expenditure (70%) was incurred on 11.9 per cent of the medicines prescribed. The per capita expenditure was significantly higher in individuals with comorbidities (P=0.03) and those who had a longer duration of hospital stay (P<0.0001). About 28.1 per cent prescriptions were inappropriate. ADRs (140) were observed in 139 (13.9%) inpatients. Individuals with inappropriate medicines prescriptions and ADRs had a longer duration of hospital stay and more number of medicines prescribed.

Interpretation conclusions: Comorbidities, prolonged hospitalization, polypharmacy, inappropriate medicines and parenteral medicines being prescribed contribute to increased expenditure on medicines in geriatric inpatients. In view of the rising number of geriatric inpatients, there is a need to frame a drug policy for them along with surveillance of expenditure on prescribed medicines. This needs to be treated as a priority.

背景目标:医疗保健支出是老年群体关注的主要问题。本研究旨在评估老年住院病人的用药支出模式:方法:对 1000 名年龄≥60 岁的老年住院病人进行了观察研究。研究收集了有关人口统计学特征、处方药物、药物支出、处方药物的适当性和药物不良反应(ADRs)的数据。处方药物的适当性是根据美国老年医学会 2015 年更新的比尔斯标准确定的:研究期间,老年病住院患者占病房住院总人数的 41.3%。共开出 127 种配方的 8366 种药品。处方药总支出为 1,087,175 印度卢比,人均支出为 1087.17 印度卢比。肠外用药占药品支出的 91%。11.9% 的处方药支出最高(70%)。合并症患者(P=0.03)和住院时间较长的患者的人均支出明显较高(P解释结论:合并症、住院时间长、使用多种药物、用药不当和开具肠外药物是导致老年住院病人药费支出增加的原因。鉴于老年住院病人的数量不断增加,有必要为他们制定一项药物政策,同时对处方药的支出进行监控。这需要作为一个优先事项来处理。
{"title":"Pharmacoeconomics of medicines used for geriatric individuals in a tertiary care hospital in Delhi.","authors":"Vikram Jit Singh, Vandana Roy, Shubha Singhal, M K Daga","doi":"10.4103/ijmr.ijmr_2507_21","DOIUrl":"10.4103/ijmr.ijmr_2507_21","url":null,"abstract":"<p><strong>Background objectives: </strong>Expenditure on healthcare is a major concern in the geriatric age group. The current study was carried out to assess the expenditure patterns on medicines utilized in geriatric inpatients.</p><p><strong>Methods: </strong>An observational study was conducted on 1000 geriatric inpatients, aged ≥60 yr, admitted to the medicine unit. Data were collected regarding demographic characteristics, prescribed medicines, expenditure incurred on medicines, appropriateness of medicines prescribed and adverse drug reactions (ADRs). Appropriateness of the prescribed medicines was determined using the American Geriatrics Society 2015 Updated Beers Criteria.</p><p><strong>Results: </strong>Geriatric inpatients comprised 41.3 per cent of the total individuals admitted in the ward during the study period. A total of 8366 medicines were prescribed in 127 formulations. The total expenditure on prescribed medicines was INR 1,087,175 with a per capita expenditure of INR 1087.17. Parenteral medicines accounted for 91 per cent of the expenditure on medicines. Maximum expenditure (70%) was incurred on 11.9 per cent of the medicines prescribed. The per capita expenditure was significantly higher in individuals with comorbidities (P=0.03) and those who had a longer duration of hospital stay (P<0.0001). About 28.1 per cent prescriptions were inappropriate. ADRs (140) were observed in 139 (13.9%) inpatients. Individuals with inappropriate medicines prescriptions and ADRs had a longer duration of hospital stay and more number of medicines prescribed.</p><p><strong>Interpretation conclusions: </strong>Comorbidities, prolonged hospitalization, polypharmacy, inappropriate medicines and parenteral medicines being prescribed contribute to increased expenditure on medicines in geriatric inpatients. In view of the rising number of geriatric inpatients, there is a need to frame a drug policy for them along with surveillance of expenditure on prescribed medicines. This needs to be treated as a priority.</p>","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":"159 2","pages":"143-152"},"PeriodicalIF":4.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11050745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140856190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Navigating cancer care in India: Reflections & imperatives. 印度癌症护理导航:思考与当务之急。
IF 4.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2024-02-01 Epub Date: 2024-04-04 DOI: 10.4103/ijmr.ijmr_240_24
Sudeep Gupta
{"title":"Navigating cancer care in India: Reflections & imperatives.","authors":"Sudeep Gupta","doi":"10.4103/ijmr.ijmr_240_24","DOIUrl":"10.4103/ijmr.ijmr_240_24","url":null,"abstract":"","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":" ","pages":"117-119"},"PeriodicalIF":4.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11050746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139930906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of liver segmental dose threshold for hepatocyte regeneration following liver stereotactic body radiation therapy. 评估肝脏立体定向体放射治疗后肝细胞再生的肝段剂量阈值。
IF 4.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2024-02-01 Epub Date: 2024-04-04 DOI: 10.4103/ijmr.ijmr_1171_21
Karishma George, Supriya Chopra, Karthick Rajamanickam, Kishore Joshi, Jamema Swamidas, Nitin Shetty, Reena Engineer

Background objectives: There is limited evidence studying the relationship of liver segmental dose and segmental volume changes. The segmental dose thresholds could potentially allow for segmental regeneration after liver stereotactic body radiation therapy (SBRT). Given improved survival in hepatocellular cancer (HCC) and liver metastases and more salvage therapy options, this has become an important clinical question to explore. This study assesses the impact of liver segmental dose on segmental volume changes (gain or loss) after SBRT.

Methods: Liver segmental contours were delineated on baseline and serial follow up triphasic computed tomography scans. The volumes of total liver and doses to total liver, uninvolved liver and individual segments were noted. A correlation was evaluated between liver/segmental volume and dose using Pearson's correlation. Furthermore, receiver operator's curve (ROC) analysis was performed to find the segmental dose, i.e . predictive for liver volume loss.

Results: A total of 140 non-tumour liver segments were available for analysis in 21 participants. Overall, 13 participants showed loss of overall liver volume and eight showed gain of overall liver volume. The median dose in segments reporting an increase in volume was 9.1 Gy (7-36 Gy). The median dose in segments losing volume was 15.5 Gy (1-49 Gy). On ROC analysis, segmental dose >11 Gy was associated with volume loss. On univariate analysis, only liver segmental dose contributed to a significant segmental volume loss.

Interpretation conclusions: We propose from the findings of this study that in SBRT for large hepatocellular cancer or liver metastases, liver segments should be individually delineated. Furthermore, 3-5 liver segments may be preferentially subjected to <9 Gy to facilitate hepatocyte regeneration. Preferential sparing of uninvolved liver segments may improve outcomes in liver stereotaxyas lower segmental doses were associated with liver regeneration. This may have implications on future liver SBRT planning where segmental doses may be as important as the mean dose.

背景目标:研究肝段剂量与肝段体积变化关系的证据有限。节段剂量阈值有可能使肝脏立体定向体放射治疗(SBRT)后的节段再生。鉴于肝细胞癌(HCC)和肝转移瘤的生存率有所提高,挽救治疗的选择也越来越多,这已成为一个需要探讨的重要临床问题。本研究评估了肝段剂量对 SBRT 后肝段体积变化(增大或缩小)的影响:方法:在基线和连续随访的三相计算机断层扫描上划定肝段轮廓。方法:在基线和连续随访的三相计算机断层扫描中划定肝脏节段轮廓,并记录总肝脏体积以及总肝脏、未受累肝脏和单个节段的剂量。利用皮尔逊相关性评估了肝脏/肝段体积与剂量之间的相关性。此外,还进行了受体运算曲线(ROC)分析,以找出节段剂量,即预测肝脏体积损失的剂量:结果:21 名参与者共有 140 个非肿瘤肝节段可供分析。总体而言,13 名参与者的肝脏总体积减少,8 名参与者的肝脏总体积增加。报告体积增加的肝段的中位剂量为 9.1 Gy(7-36 Gy)。肝脏体积减少区段的中位剂量为 15.5 Gy(1-49 Gy)。在 ROC 分析中,分段剂量 >11 Gy 与容积损失有关。在单变量分析中,只有肝节段剂量导致了显著的节段体积损失:根据这项研究的结果,我们建议在对大肝细胞癌或肝转移瘤进行 SBRT 治疗时,应单独划分肝段。此外,3-5 个肝段可优先接受 SBRT 治疗。
{"title":"Evaluation of liver segmental dose threshold for hepatocyte regeneration following liver stereotactic body radiation therapy.","authors":"Karishma George, Supriya Chopra, Karthick Rajamanickam, Kishore Joshi, Jamema Swamidas, Nitin Shetty, Reena Engineer","doi":"10.4103/ijmr.ijmr_1171_21","DOIUrl":"10.4103/ijmr.ijmr_1171_21","url":null,"abstract":"<p><strong>Background objectives: </strong>There is limited evidence studying the relationship of liver segmental dose and segmental volume changes. The segmental dose thresholds could potentially allow for segmental regeneration after liver stereotactic body radiation therapy (SBRT). Given improved survival in hepatocellular cancer (HCC) and liver metastases and more salvage therapy options, this has become an important clinical question to explore. This study assesses the impact of liver segmental dose on segmental volume changes (gain or loss) after SBRT.</p><p><strong>Methods: </strong>Liver segmental contours were delineated on baseline and serial follow up triphasic computed tomography scans. The volumes of total liver and doses to total liver, uninvolved liver and individual segments were noted. A correlation was evaluated between liver/segmental volume and dose using Pearson's correlation. Furthermore, receiver operator's curve (ROC) analysis was performed to find the segmental dose, i.e . predictive for liver volume loss.</p><p><strong>Results: </strong>A total of 140 non-tumour liver segments were available for analysis in 21 participants. Overall, 13 participants showed loss of overall liver volume and eight showed gain of overall liver volume. The median dose in segments reporting an increase in volume was 9.1 Gy (7-36 Gy). The median dose in segments losing volume was 15.5 Gy (1-49 Gy). On ROC analysis, segmental dose >11 Gy was associated with volume loss. On univariate analysis, only liver segmental dose contributed to a significant segmental volume loss.</p><p><strong>Interpretation conclusions: </strong>We propose from the findings of this study that in SBRT for large hepatocellular cancer or liver metastases, liver segments should be individually delineated. Furthermore, 3-5 liver segments may be preferentially subjected to <9 Gy to facilitate hepatocyte regeneration. Preferential sparing of uninvolved liver segments may improve outcomes in liver stereotaxyas lower segmental doses were associated with liver regeneration. This may have implications on future liver SBRT planning where segmental doses may be as important as the mean dose.</p>","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":" ","pages":"232-240"},"PeriodicalIF":4.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11050757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140039254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low abundance of healthy bacteria in the gastric microbiota can be a potential biomarker for gastrointestinal diseases: A pilot study. 胃微生物群中健康细菌的低丰度可作为胃肠道疾病的潜在生物标志物:一项试点研究。
IF 4.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2024-02-01 Epub Date: 2024-04-04 DOI: 10.4103/ijmr.ijmr_864_23
Safiya Arfi, Prateek Sharma, Kunal Das, Yogendra Bhaskar, Isha Goel, Harpreet Singh, Rajashree Das
{"title":"Low abundance of healthy bacteria in the gastric microbiota can be a potential biomarker for gastrointestinal diseases: A pilot study.","authors":"Safiya Arfi, Prateek Sharma, Kunal Das, Yogendra Bhaskar, Isha Goel, Harpreet Singh, Rajashree Das","doi":"10.4103/ijmr.ijmr_864_23","DOIUrl":"10.4103/ijmr.ijmr_864_23","url":null,"abstract":"","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":" ","pages":"254-258"},"PeriodicalIF":4.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11050751/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140131354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of MUC5B promoter polymorphism with interstitial lung changes after COVID-19: A preliminary observation. MUC5B启动子多态性与COVID-19后肺间质变化的关系:初步观察
IF 4.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2024-01-01 Epub Date: 2024-03-04 DOI: 10.4103/ijmr.ijmr_137_23
Sahajal Dhooria, Amanjit Bal, Riya Sharma, Nidhi Prabhakar, Siddhant Arora, Inderpaul Singh Sehgal, Dharambir Kashyap, Mandeep Garg, Ashish Bhalla, Ashutosh Nath Aggarwal, Ritesh Agarwal
{"title":"Association of MUC5B promoter polymorphism with interstitial lung changes after COVID-19: A preliminary observation.","authors":"Sahajal Dhooria, Amanjit Bal, Riya Sharma, Nidhi Prabhakar, Siddhant Arora, Inderpaul Singh Sehgal, Dharambir Kashyap, Mandeep Garg, Ashish Bhalla, Ashutosh Nath Aggarwal, Ritesh Agarwal","doi":"10.4103/ijmr.ijmr_137_23","DOIUrl":"10.4103/ijmr.ijmr_137_23","url":null,"abstract":"","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":" ","pages":"109-113"},"PeriodicalIF":4.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10954098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139722384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation of severity & clinical outcomes of COVID-19 with virus variants: A prospective, multicentre hospital network study. COVID-19 严重程度和临床结果与病毒变种的相关性:一项前瞻性多中心医院网络研究。
IF 4.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2024-01-01 Epub Date: 2024-03-04 DOI: 10.4103/ijmr.ijmr_1041_23
Komal Wadhwa, Shilpa Malik, Srinigila Balaji, Ramachandran Thiruvengadam, Murali Dharan Bashyam, Prasanta Kumar Bhattacharya, Bijayini Behera, Pankaj Bhardwaj, Nidhan K Biswas, Asim Das, Anindya Dey, Dhiraj Dhotre, Mary Dias, Pankaj Dubey, Shreelekha Dutta, Ravisekhar Gadepalli, Mudita Gosain, Kalal Iravaty Goud, Neeraj Kumar Gupta, Nitesh Gupta, Pradipta Jana, Deepak Jena, Elizabeth John, Arunkumar Karunanidhi, S Muhammad Salim Khan, Sahil Khattar, Abhilash Prabhakar Kundavaram Paul, Shakti Kumar, Arindam Maitra, Nikhil Modi, Mahesh Moorthy, Savitha Nagaraj, Dasaradhi Palakodeti, Anil Kumar Pandey, Aparna Pandey, Sunil Kumar Raghav, Suresh Ramasubban, Sreevatsan Raghavan, S Harikrishnan, S Krishnamoorthy, Selvaraj Selvamurugan, Raman Sardana, Yogesh Shouche, Akanksha Singh, Arvind Kumar Singh, V Ramasubramaniyan, Monika Yadav, Danish Zahoor, Suneetha Narreddy, Shinjini Bhatnagar, Nitya Wadhwa, Bhabatosh Das, Pramod Kumar Garg

Background objectives: The clinical course of COVID-19 and its prognosis are influenced by both viral and host factors. The objectives of this study were to develop a nationwide platform to investigate the molecular epidemiology of SARS-CoV-2 (Severe acute respiratory syndrome Corona virus 2) and correlate the severity and clinical outcomes of COVID-19 with virus variants.

Methods: A nationwide, longitudinal, prospective cohort study was conducted from September 2021 to December 2022 at 14 hospitals across the country that were linked to a viral sequencing laboratory under the Indian SARS-CoV-2 Genomics Consortium. All participants (18 yr and above) who attended the hospital with a suspicion of SARS-CoV-2 infection and tested positive by the reverse transcription-PCR method were included. The participant population consisted of both hospitalized as well as outpatients. Their clinical course and outcomes were studied prospectively. Nasopharyngeal samples collected were subjected to whole genome sequencing to detect SARS-CoV-2 variants.

Results: Of the 4972 participants enrolled, 3397 provided samples for viral sequencing and 2723 samples were successfully sequenced. From this, the evolution of virus variants of concern including Omicron subvariants which emerged over time was observed and the same reported here. The mean age of the study participants was 41 yr and overall 49.3 per cent were female. The common symptoms were fever and cough and 32.5 per cent had comorbidities. Infection with the Delta variant evidently increased the risk of severe COVID-19 (adjusted odds ratio: 2.53, 95% confidence interval: 1.52, 4.2), while Omicron was milder independent of vaccination status. The independent risk factors for mortality were age >65 yr, presence of comorbidities and no vaccination.

Interpretation conclusions: The authors believe that this is a first-of-its-kind study in the country that provides real-time data of virus evolution from a pan-India network of hospitals closely linked to the genome sequencing laboratories. The severity of COVID-19 could be correlated with virus variants with Omicron being the milder variant.

背景目标:COVID-19 的临床过程及其预后受病毒和宿主因素的影响。本研究的目的是在全国范围内建立一个平台,研究 SARS-CoV-2(严重急性呼吸系统综合征科罗娜病毒 2)的分子流行病学,并将 COVID-19 的严重程度和临床结局与病毒变异体相关联。方法:2021 年 9 月至 2022 年 12 月在全国范围内开展了一项纵向前瞻性队列研究:方法:2021 年 9 月至 2022 年 12 月,在全国 14 家与印度 SARS-CoV-2 基因组学联合会病毒测序实验室相连的医院开展了一项全国性纵向前瞻性队列研究。所有因怀疑感染 SARS-CoV-2 而到医院就诊并经反转录-PCR 方法检测呈阳性的患者(18 岁及以上)均被纳入研究范围。参与者既包括住院病人,也包括门诊病人。对他们的临床过程和结果进行了前瞻性研究。对采集的鼻咽部样本进行了全基因组测序,以检测 SARS-CoV-2 变异:结果:在 4972 名参与者中,有 3397 人提供了病毒测序样本,其中 2723 人成功测序。从中观察到了包括随着时间推移而出现的 Omicron 亚变种在内的相关病毒变种的演变情况,并在此进行了报告。研究参与者的平均年龄为 41 岁,49.3% 为女性。常见症状是发烧和咳嗽,32.5%的人有合并症。感染德尔塔变异株会明显增加罹患严重 COVID-19 的风险(调整后的几率比:2.53,95% 置信区间:1.52, 4.2),而感染奥米克龙变异株的风险较轻,与疫苗接种情况无关。死亡率的独立风险因素是年龄大于 65 岁、存在合并症和未接种疫苗:作者认为,这是印度首次通过与基因组测序实验室紧密相连的泛印度医院网络提供病毒演变的实时数据。COVID-19 的严重程度可能与病毒变种有关,Omicron 是较温和的变种。
{"title":"Correlation of severity & clinical outcomes of COVID-19 with virus variants: A prospective, multicentre hospital network study.","authors":"Komal Wadhwa, Shilpa Malik, Srinigila Balaji, Ramachandran Thiruvengadam, Murali Dharan Bashyam, Prasanta Kumar Bhattacharya, Bijayini Behera, Pankaj Bhardwaj, Nidhan K Biswas, Asim Das, Anindya Dey, Dhiraj Dhotre, Mary Dias, Pankaj Dubey, Shreelekha Dutta, Ravisekhar Gadepalli, Mudita Gosain, Kalal Iravaty Goud, Neeraj Kumar Gupta, Nitesh Gupta, Pradipta Jana, Deepak Jena, Elizabeth John, Arunkumar Karunanidhi, S Muhammad Salim Khan, Sahil Khattar, Abhilash Prabhakar Kundavaram Paul, Shakti Kumar, Arindam Maitra, Nikhil Modi, Mahesh Moorthy, Savitha Nagaraj, Dasaradhi Palakodeti, Anil Kumar Pandey, Aparna Pandey, Sunil Kumar Raghav, Suresh Ramasubban, Sreevatsan Raghavan, S Harikrishnan, S Krishnamoorthy, Selvaraj Selvamurugan, Raman Sardana, Yogesh Shouche, Akanksha Singh, Arvind Kumar Singh, V Ramasubramaniyan, Monika Yadav, Danish Zahoor, Suneetha Narreddy, Shinjini Bhatnagar, Nitya Wadhwa, Bhabatosh Das, Pramod Kumar Garg","doi":"10.4103/ijmr.ijmr_1041_23","DOIUrl":"10.4103/ijmr.ijmr_1041_23","url":null,"abstract":"<p><strong>Background objectives: </strong>The clinical course of COVID-19 and its prognosis are influenced by both viral and host factors. The objectives of this study were to develop a nationwide platform to investigate the molecular epidemiology of SARS-CoV-2 (Severe acute respiratory syndrome Corona virus 2) and correlate the severity and clinical outcomes of COVID-19 with virus variants.</p><p><strong>Methods: </strong>A nationwide, longitudinal, prospective cohort study was conducted from September 2021 to December 2022 at 14 hospitals across the country that were linked to a viral sequencing laboratory under the Indian SARS-CoV-2 Genomics Consortium. All participants (18 yr and above) who attended the hospital with a suspicion of SARS-CoV-2 infection and tested positive by the reverse transcription-PCR method were included. The participant population consisted of both hospitalized as well as outpatients. Their clinical course and outcomes were studied prospectively. Nasopharyngeal samples collected were subjected to whole genome sequencing to detect SARS-CoV-2 variants.</p><p><strong>Results: </strong>Of the 4972 participants enrolled, 3397 provided samples for viral sequencing and 2723 samples were successfully sequenced. From this, the evolution of virus variants of concern including Omicron subvariants which emerged over time was observed and the same reported here. The mean age of the study participants was 41 yr and overall 49.3 per cent were female. The common symptoms were fever and cough and 32.5 per cent had comorbidities. Infection with the Delta variant evidently increased the risk of severe COVID-19 (adjusted odds ratio: 2.53, 95% confidence interval: 1.52, 4.2), while Omicron was milder independent of vaccination status. The independent risk factors for mortality were age >65 yr, presence of comorbidities and no vaccination.</p><p><strong>Interpretation conclusions: </strong>The authors believe that this is a first-of-its-kind study in the country that provides real-time data of virus evolution from a pan-India network of hospitals closely linked to the genome sequencing laboratories. The severity of COVID-19 could be correlated with virus variants with Omicron being the milder variant.</p>","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":" ","pages":"91-101"},"PeriodicalIF":4.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10954099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139722385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Authors' response. 作者回复。
IF 4.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2024-01-01 Epub Date: 2024-03-04 DOI: 10.4103/IJMR.IJMR_265_24
Manickam Ponnaiah, Tarun Bhatnagar, Rizwan Suliankachi Abdulkader, Rajalakshmi Elumalai, Janani Surya, Kathiresan Jeyashree, Muthusamy Santhosh Kumar, Ranjithkumar Govindaraju, Jeromie Wesley Vivian Thangaraj, Hari Krishan Aggarwal, Suresh Balan, Tridip Dutta Baruah, Ayan Basu, Yogita Bavaskar, Ajeet Singh Bhadoria, Ashish Bhalla, Pankaj Bhardwaj, Rachana Bhat, Jaya Chakravarty, Gina Maryann Chandy, Bal Kishan Gupta, Rakesh Kakkar, Ali Hasan Faiz Karnam, Sushila Kataria, Janakkumar Khambholja, Dewesh Kumar, Nithin Kumar, Monaliza Lyngdoh, M Selva Meena, Kedar Mehta, M P Sheethal, Subhasis Mukherjee, Anuj Mundra, Arun Murugan, Seetharaman Narayanan, Balamurugan Nathan, Jutika Ojah, Pushpa Patil, Sunita Pawar, A Charles Pon Ruban, R Vadivelu, Rishabh Kumar Rana, S Nagendra Boopathy, S Priya, Saroj Kumar Sahoo, Arti Shah, Mohammad Shameem, Karthikeyan Shanmugam, Sachin K Shivnitwar, Abhishek Singhai, Saurabh Srivastava, Sudheera Sulgante, Arunansu Talukdar, Alka Verma, Rajaat Vohra, Rabbanie Tariq Wani, Bhargavi Bathula, Gayathri Kumari, Divya Saravana Kumar, Aishwariya Narasimhan, N C Krupa, Thirumaran Senguttuvan, Parvathi Surendran, Dharsikaa Tamilmani, Alka Turuk, Gunjan Kumar, Aparna Murkherjee, Rakesh Aggarwal, Manoj Vasant Murhekar
{"title":"Authors' response.","authors":"Manickam Ponnaiah, Tarun Bhatnagar, Rizwan Suliankachi Abdulkader, Rajalakshmi Elumalai, Janani Surya, Kathiresan Jeyashree, Muthusamy Santhosh Kumar, Ranjithkumar Govindaraju, Jeromie Wesley Vivian Thangaraj, Hari Krishan Aggarwal, Suresh Balan, Tridip Dutta Baruah, Ayan Basu, Yogita Bavaskar, Ajeet Singh Bhadoria, Ashish Bhalla, Pankaj Bhardwaj, Rachana Bhat, Jaya Chakravarty, Gina Maryann Chandy, Bal Kishan Gupta, Rakesh Kakkar, Ali Hasan Faiz Karnam, Sushila Kataria, Janakkumar Khambholja, Dewesh Kumar, Nithin Kumar, Monaliza Lyngdoh, M Selva Meena, Kedar Mehta, M P Sheethal, Subhasis Mukherjee, Anuj Mundra, Arun Murugan, Seetharaman Narayanan, Balamurugan Nathan, Jutika Ojah, Pushpa Patil, Sunita Pawar, A Charles Pon Ruban, R Vadivelu, Rishabh Kumar Rana, S Nagendra Boopathy, S Priya, Saroj Kumar Sahoo, Arti Shah, Mohammad Shameem, Karthikeyan Shanmugam, Sachin K Shivnitwar, Abhishek Singhai, Saurabh Srivastava, Sudheera Sulgante, Arunansu Talukdar, Alka Verma, Rajaat Vohra, Rabbanie Tariq Wani, Bhargavi Bathula, Gayathri Kumari, Divya Saravana Kumar, Aishwariya Narasimhan, N C Krupa, Thirumaran Senguttuvan, Parvathi Surendran, Dharsikaa Tamilmani, Alka Turuk, Gunjan Kumar, Aparna Murkherjee, Rakesh Aggarwal, Manoj Vasant Murhekar","doi":"10.4103/IJMR.IJMR_265_24","DOIUrl":"10.4103/IJMR.IJMR_265_24","url":null,"abstract":"","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":" ","pages":"44-45"},"PeriodicalIF":4.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10954097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139897966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ABDpred: Prediction of active antimicrobial compounds using supervised machine learning techniques. ABDpred:使用监督机器学习技术预测活性抗菌化合物。
IF 4.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2024-01-01 Epub Date: 2024-03-04 DOI: 10.4103/ijmr.ijmr_1832_22
Tanmoy Jana, Debasree Sarkar, Debayan Ganguli, Sandip Kumar Mukherjee, Rahul Shubhra Mandal, Santasabuj Das

Background objectives: Discovery of new antibiotics is the need of the hour to treat infectious diseases. An ever-increasing repertoire of multidrug-resistant pathogens poses an imminent threat to human lives across the globe. However, the low success rate of the existing approaches and technologies for antibiotic discovery remains a major bottleneck. In silico methods like machine learning (ML) deem more promising to meet the above challenges compared with the conventional experimental approaches. The goal of this study was to create ML models that may be used to successfully predict new antimicrobial compounds.

Methods: In this article, we employed eight different ML algorithms namely, extreme gradient boosting, random forest, gradient boosting classifier, deep neural network, support vector machine, multilayer perceptron, decision tree, and logistic regression. These models were trained using a dataset comprising 312 antibiotic drugs and a negative set of 936 non-antibiotic drugs in a five-fold cross validation approach.

Results: The top four ML classifiers (extreme gradient boosting, random forest, gradient boosting classifier and deep neural network) were able to achieve an accuracy of 80 per cent and above during the evaluation of testing and blind datasets.

Interpretation conclusions: We aggregated the top performing four models through a soft-voting technique to develop an ensemble-based ML method and incorporated it into a freely accessible online prediction server named ABDpred ( http://clinicalmedicinessd.com.in/abdpred/ ).

背景目标:发现新的抗生素是治疗传染病的当务之急。日益增多的多重耐药病原体对全球人类的生命构成了迫在眉睫的威胁。然而,现有抗生素发现方法和技术的低成功率仍然是一个主要瓶颈。与传统的实验方法相比,机器学习(ML)等硅学方法更有希望应对上述挑战。本研究的目标是创建可用于成功预测新抗菌化合物的 ML 模型:在本文中,我们采用了八种不同的 ML 算法,即极端梯度提升、随机森林、梯度提升分类器、深度神经网络、支持向量机、多层感知器、决策树和逻辑回归。这些模型采用五倍交叉验证法,使用由 312 种抗生素药物和 936 种非抗生素药物组成的数据集进行训练:在对测试数据集和盲数据集进行评估期间,排名前四位的多重层流分类器(极梯度提升、随机森林、梯度提升分类器和深度神经网络)的准确率均达到 80% 及以上:我们通过软投票技术汇总了表现最好的四个模型,开发出一种基于集合的 ML 方法,并将其纳入一个可免费访问的在线预测服务器,名为 ABDpred (http://clinicalmedicinessd.com.in/abdpred/)。
{"title":"ABDpred: Prediction of active antimicrobial compounds using supervised machine learning techniques.","authors":"Tanmoy Jana, Debasree Sarkar, Debayan Ganguli, Sandip Kumar Mukherjee, Rahul Shubhra Mandal, Santasabuj Das","doi":"10.4103/ijmr.ijmr_1832_22","DOIUrl":"10.4103/ijmr.ijmr_1832_22","url":null,"abstract":"<p><strong>Background objectives: </strong>Discovery of new antibiotics is the need of the hour to treat infectious diseases. An ever-increasing repertoire of multidrug-resistant pathogens poses an imminent threat to human lives across the globe. However, the low success rate of the existing approaches and technologies for antibiotic discovery remains a major bottleneck. In silico methods like machine learning (ML) deem more promising to meet the above challenges compared with the conventional experimental approaches. The goal of this study was to create ML models that may be used to successfully predict new antimicrobial compounds.</p><p><strong>Methods: </strong>In this article, we employed eight different ML algorithms namely, extreme gradient boosting, random forest, gradient boosting classifier, deep neural network, support vector machine, multilayer perceptron, decision tree, and logistic regression. These models were trained using a dataset comprising 312 antibiotic drugs and a negative set of 936 non-antibiotic drugs in a five-fold cross validation approach.</p><p><strong>Results: </strong>The top four ML classifiers (extreme gradient boosting, random forest, gradient boosting classifier and deep neural network) were able to achieve an accuracy of 80 per cent and above during the evaluation of testing and blind datasets.</p><p><strong>Interpretation conclusions: </strong>We aggregated the top performing four models through a soft-voting technique to develop an ensemble-based ML method and incorporated it into a freely accessible online prediction server named ABDpred ( http://clinicalmedicinessd.com.in/abdpred/ ).</p>","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":" ","pages":"78-90"},"PeriodicalIF":4.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10954100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139722383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sudden deaths among adults in India: Some observations. 印度成年人中的猝死:一些观察结果。
IF 4.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2024-01-01 Epub Date: 2024-03-04 DOI: 10.4103/ijmr.ijmr_2434_23
Bhaskaran Raman, Sai Mahesh Vajjala
{"title":"Sudden deaths among adults in India: Some observations.","authors":"Bhaskaran Raman, Sai Mahesh Vajjala","doi":"10.4103/ijmr.ijmr_2434_23","DOIUrl":"10.4103/ijmr.ijmr_2434_23","url":null,"abstract":"","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":" ","pages":"43-44"},"PeriodicalIF":4.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10954096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139897967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Indian Journal of Medical Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1